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Frailty as a Predictor of Alzheimer’s Disease, Vascular Dementia, and All Dementia 
among Community-Dwelling Older People: A Systematic Review and Meta-analysis 
 
ABSTRACT 
Objective: To perform a systematic search of the literature for currently available evidence 
on frailty as a predictor of dementia and to conduct a meta-analysis to synthesize the pooled 
risk estimates among community-dwelling older people. 
 
Design: A systematic review and meta-analysis. 
 
Data Sources: Embase, MEDLINE, CINAHL Plus, PsycINFO, and the Cochrane Library 
from 2000 to January 2016, and reference lists of relevant articles. 
 
Eligibility Criteria: Any studies that prospectively examined the incident risks of dementia 
with frailty among community-dwelling older people without language restriction. 
 
Results:  Of 2,565 studies identified through the systematic review, seven studies were 
included in this review. Of these, four studies reported hazard ratios (HR) of incident 
dementia for physical frailty defined by Cardiovascular Health Study criteria and were 
included in a meta-analysis. Frailty was a significant predictor of incident Alzheimer’s 
disease (four studies: pooled HR=1.28, 95% confidence interval (95%CI)=1.00-1.63, 
p=0.05), vascular dementia (two studies: pooled HR=2.70, 95%CI=1.40-5.23, p=0.003), and 
all dementia (three studies: pooled HR=1.33, 95%CI=1.07-1.67, p=0.01). Heterogeneity 
across the studies was low to modest (I2=0-51%). A random-effects meta-regression analysis 
showed that the female proportion of the cohort primarily mediated the association of frailty 
with Alzheimer’s disease (female proportion coefficient=0.04, 95%CI=0.01-0.08, p=0.01). 
 
Conclusion: This systematic review and meta-analysis suggests that frailty was a significant 
predictor of Alzheimer’s disease, vascular dementia, and all dementia among community-
dwelling older people. Frail women may have a higher risk of incident Alzheimer’s disease 
than frail men. 
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INTRODUCTION 
Dementia is a neurocognitive disorder characterized by deteriorations in memory, language, 
and other cognitive functions, and influences an individual’s ability to perform every day 
activities.1 Dementia typically is a major cause of disability and dependence in older adults2 
and nearly 35.6 million people live with dementia worldwide.3 The prevalence of dementia in 
people age 60 years or older is 5–7%,2 which increases with age, and approximately one-third 
of people have dementia when they die.4 Given that currently available pharmacological 
interventions can neither cure nor reverse dementia (but only offer limited symptom 
modification), it is a pressing issue to identify potentially modifiable risk factors for 
dementia.5,6  
 
One of the possible candidates is frailty. Frailty is a geriatric syndrome with the main features 
of age-related decline in multi-system physiological reserve and reduction in the ability to 
tolerate external and internal stressors, leading to vulnerability to adverse health outcomes.7 A 
physical phonotype of frailty8 has been characterized as having low energy, low physical 
activity, slow gait speed, weakness, and weight loss. The adverse outcomes associated with 
frailty include disability, falls, hospitalization, institutionalization, fracture, poor quality of 
life, and mortality.7-12 The prevalence rates vary, ranging from 4.0% to 59.1%, and an overall 
weighted prevalence rate is 10.7% in community-dwelling older adults aged 65 or more.13 
Approximately 25% of people aged 85 or more13 and more than 50% of institutionalized 
people14 are frail. 
 
Although frailty has been studied for various adverse outcomes,7 a limited number of studies 
have investigated prospective associations of frailty with dementia and reported inconsistent 
results.15-18 Among five studies that examined association between baseline frailty and 
subsequent Alzheimer’s disease, only one study16 showed a significant association while the 
rest of the studies15,17-19 showed negative results. Furthermore, two studies reported that 
individuals with frailty at baseline had significantly higher risk for all type dementia 
compared with non-frail counterparts,17,20 but two other studies did not.15,18  
 
Recently two systematic review articles summarized associations of frailty with dementia.21,22 
The first was a systematic review of the literature up to 201021 and identified only one 
prospective study of associations between frailty and Alzheimer’s disease.16 The second 
review identified three previous studies that examined baseline frailty and subsequent 
Alzheimer’s disease16,17,19 and conducted a meta-analysis. However, this meta-analysis was 
statistically compromised by combining different types of effect measures and using different 
frailty criteria. In addition, this review paper did not include important studies.15,18 Therefore 
the associations of frailty with Alzheimer’s disease and other dementias are still to be 
elucidated and reliable pooled evidence is needed. The current systematic review and meta-
analysis had two objectives: to perform a comprehensive systematic search of the literature 
on the associations of frailty with dementia among community-dwelling older people, and to 
conduct a meta-analysis to synthesize the pooled risk estimates. 
 
METHOD 
Data Sources and Search Strategy 
A systematic literature search was conducted in January 2016 based on a protocol developed 
in accordance with Preferred Reporting Items for Systematic Review and Meta-Analyses 
(PRISMA)23 and Meta-analysis of Observational Studies in Epidemiology (MOOSE)24 
statements. Five electronic databases (Embase, MEDLINE, CINAHL Plus, PsycINFO, and 
the Cochrane Library) were searched for studies published in 2000 or later without language 
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restriction and with an explosion function if available. The publication period was decided 
based on the fact the most widely used definition of frailty, Fried phenotype, was published in 
2001.8 
 
The search terms used included as follows: 
(Dementia (Medical Subject Heading (MeSH))) OR (Alzheimer(’s) Disease (MeSH)) OR 
(Dementia with Lewy Bodies (MeSH)) OR (Lewy Body Disease (MeSH)) OR (Multiinfarct 
Dementia (MeSH)) OR (Dementia, Multi-Infarct (MeSH)) OR (Vascular Dementia (MeSH)) 
OR (Dementia, Vascular (MeSH)) OR (Frontotemporal Dementia (MeSH)) OR (Frontal 
Variant Frontotemporal Dementia (MeSH)) OR (Dementia, Senile (MeSH)) OR (Senile 
Dementia (MeSH)) OR (Presenile Dementia (MeSH)) OR (Dementia, Presenile (MeSH)) OR 
(Delirium, Dementia, Amnestic, Cognitive Disorders (MeSH)) OR (dementia) OR 
(alzheimer) 
AND 
(Frail Elderly (MeSH)) OR (Frailty Syndrome (MeSH)) OR (Frailty). 
Bibliographies of included and relevant studies and review articles were manually searched. 
Studies known to the authors were also reviewed for references. 
 
Study Selection 
All prospective studies that examined baseline frailty status according to criteria which have 
been specifically designed for frailty and validated in population-based studies and 
subsequent incident dementia if any kind among community-dwelling older adults aged 65 or 
older were potentially eligible. Frailty status included, where applicable, both frail and 
prefrail groups. For example in studies using the Fried phenotype to determine frailty status, 
those scoring 0 are robust, 1-2 are prefrail and 3 or more are frail. The baseline cohorts 
should be dementia-free and dementia should be diagnosed based on established diagnostic 
criteria such as Diagnostic and Statistical Manual of Mental Disorders (DSM) or National 
Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease 
and Related Disorders Association criteria (NINCDS-ADRDA). Mild cognitive impairment 
(MCI) or cognitive changes as an outcome were not considered in this study. Studies were 
excluded if they were review papers, randomized controlled trials, conference abstracts, 
editorials, or comments. When the same cohort was used by multiple studies, the one with a 
longer follow-up period or a larger sample size was chosen for a meta-analysis. An adjusted 
effect measure was preferred when a study reported adjusted and unadjusted ones. Two 
researchers (GK and YT) independently screened title, abstract, and full-text of all studies 
identified by the literature search for eligibility. Disagreements were resolved by discussion. 
 
Data Extraction 
The two researchers (GK and YT) independently extracted characteristics of the included 
studies, including first author, study cohort name, publication year, location, sample size 
(analysis of interest or the entire cohort), proportion of female participants, age (mean and 
range or age criterion for inclusion), frailty criteria, dementia outcome, dementia criteria, 
effect measure, and follow-up period, as well as study findings which included risk estimates, 
such as OR or HR, along with 95% confidence intervals and covariates used for adjustment in 
the final models. 
 
Methodological Quality Assessment 
Studies presumed as eligible through title, abstract, and full-text screening were examined for 
methodological quality using the 9-scale Newcastle-Ottawa scale for cohort studies.25 A study 
was considered to have adequate quality of methodology when it met five or more out of nine 
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criteria. 
 
Statistical Analysis 
All analyses were performed using Review Manager 5 (version 5.2, The Cochrane 
Collaboration, Copenhagen, Denmark), Comprehensive Meta-Analysis (version 3.3, Biostat, 
New Jersey, USA), and StatsDirect (version 2.8, StatsDirect, Cheshire, UK), and the level of 
significance was set at p <0.05. 
 
Hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals of risks of incident 
dementia for frailty and prefrailty compared with non-frailty/robustness were extracted from 
the included studies according to types of dementia (Alzheimer’s disease, vascular dementia, 
or all dementia). The presence of heterogeneity across the studies was assessed using the chi 
square test and considered as present if the p value was less than 0.05. The degree of the 
heterogeneity was assessed by using I2 statistic and I2 value of 25%, 50%, and 75% were 
considered as low, moderate, and high degrees of heterogeneity, respectively.26 A fixed-
effects meta-analysis was conducted to calculate a pooled risk estimate for frail and prefrail 
groups separately using the generic inverse variance method. If heterogeneity was detected 
across the studies, a random-effects meta-analysis was used instead. Publication bias was 
assessed by visually examining a funnel plot and performing Begg-Mazumdar’s27 and 
Egger’s28 tests.  
 
The pooled risk of incident dementia by frailty was further examined using a random-effects 
meta-regression analysis to explore study characteristics, including sample size, female 
proportion of the cohort, mean age, follow-up period, and methodological quality score, for a 
possible modulator effect on the associations between frailty status and subsequent risk of 
incident dementia. 
 
RESULTS 
Selection Processes 
A systematic search of the literature using five electronic databases identified 2,564 studies, 
and one study20 was found via searching bibliographies of the relevant articles. Among the 
2,565 studies, 832 duplicate studies and 1,722 studies that were considered irrelevant to this 
review during title and abstract screening were excluded, leaving 11 studies for full-text 
review. Four studies were further excluded because two studies did not use dementia as an 
outcome and another two were editorials or comments. The remaining seven studies15-20,29 
were examined for methodological quality and considered to have adequate quality. Among 
these, four studies15-18 reporting HR of baseline frailty for risk of incident dementia were 
included in the meta-analysis. Three studies19,20,29 were not used in the meta-analysis because 
two studies19,20 did not use frailty categorization but expressed frailty status as a continuous 
score, the Frailty Index (FI), and, of the two studies using the sameThree City Study 
cohort,15,29 the one with the larger number of participants and longer follow-up period15 was 
included in the meta-analysis. A PRISMA flow chart of the literature search is shown in 
Figure 1. 
 
Study Characteristics 
Study characteristics and methodological quality score of the seven studies included in this 
study are summarized in Table 1. For study location, two studies16,17 were from the US using 
the Adult Changes in Thought17 and the Rush Memory and Aging Project16 cohorts. Two 
papers19,20 used the Canadian Study of Health and Aging cohort, and another two papers15,29 
used the Three-City Study in France. One Paper was from Italy using the Italian Longitudinal 
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Study of Aging.18 Sample size ranged from 82316 to 548015. One study20 reported the findings 
in men and women separately, while the rest used mixed cohorts. Mean age ranged from 
73.118 to 80.416, but two studies19,20 did not report it. To define frailty, five studies15-18,29 used 
modified Cardiovascular Health Study (CHS) criteria and two studies19,20 used FI. Various 
diagnostic criteria were used for dementia diagnoses, including NINCDS-ADRDA16-19, 
National Institute of Neurological and Communicative Disorders and Stroke-Association 
Internationale pour la Recherche en l’Enseignement en Neurosciences (NINCDS-AIREN)15, 
International Statistical Classification of Diseases and Related Health Problems 10th version 
(ICD-10)18, or DSM15,17-20,29. For dementia outcomes, five different outcomes were used: 
Alzheimer’s disease (n=5), vascular dementia (n=2), non-Alzheimer’s disease dementia 
(n=1), other dementia than Alzheimer’s disease and vascular dementia (n=1), and all 
dementia (n=6). Follow-up period ranged from 316 to 1019,20 years. Five studies presented 
adjusted HR of incident dementia for frailty compared with non-frailty or robustness, and two 
studies19,20 presented adjusted OR based on frailty status measured by the FI. Regarding 
assessment of methodological quality, the five studies using CHS criteria scored high at 8/9 
while the two studies using FI scored 7/919 and 6/920. 
 
Frailty as a Predictor of Incident Dementia 
Meta-analysis 
HRs from the four studies using CHS criteria to define frailty15-18 were combined to calculate 
pooled estimates according to types of dementia (Alzheimer’s disease, vascular dementia, and 
all dementia). Synthesized results showed that baseline frailty was significantly associated 
with increased risks of developing Alzheimer’s disease (4 studies15-18 : pooled HR=1.28, 
95%CI=1.00-1.63, p=0.05), vascular dementia (2 studies15,18 : pooled HR=2.70, 
95%CI=1.40-5.23, p=0.003), and all dementia (3 studies15,17,18 : pooled HR=1.33, 
95%CI=1.07-1.67, p=0.01). (Figure 2) Heterogeneity was low to moderate in these three 
study groups (I2=51%, p=0.10; I2=0%, p=0.98; I2=13%, p=0.32, respectively). Baseline 
prefrailty showed no significant associations with incident Alzheimer’s disease and all 
dementia as compared with robust individuals (2 studies15,17 : pooled HR=0.91, 95%CI=0.78-
1.08, p=0.28, 2 studies15,17 : pooled HR=0.98, 95%CI=0.85-1.14, p=0.84, respectively). Only 
one study15 examined prefrailty in relation to vascular dementia and showed nonsignificant 
result (adjusted HR=1.74, 95%CI=0.98-3.40, p=0.10). Although ORs were provided by two 
studies19,20 from the Canadian Study of Health and Aging using the FI, we did not conduct a 
meta-analysis as these studies used the same cohort. 
 
Meta-regression Analysis 
A random-effects meta-regression analysis was conducted among four studies with 
Alzheimer’s disease outcomes to investigate potential modulator effects of study 
characteristics. The other dementia outcome groups included too few studies (n<3) for this 
analysis. Among the sample size, the female proportion of the cohorts, mean age, and follow-
up period, only the female proportion was found to be a significant modulator of the 
association between frailty and incident Alzheimer’s disease (female proportion 
coefficient=0.04, 95%CI=0.01-0.08, p=0.01; intercept coefficient=-2.49, 95%CI=-4.66 to -
0.35, p=0.03). It was suggested that the female proportion explained all the between-study 
variance (R2 analog=1.00). A bubble plot with a fitted meta-regression line clearly showed 
the linear association between the female proportion of the cohorts and risks of incident 
Alzheimer’s disease according to frailty. (Figure 3). 
 
Publication Bias Assessment 
Publication bias was assessed among the four studies reporting risk of incident Alzheimer’s 
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disease. No evidence of publication bias was detected by using Begg-Mazumdar’s (p=0.75) 
and Egger’s (p=0.76) tests. The studies on vascular dementia or all dementia and the funnel 
plots could not be examined for publication bias due to the small numbers of the studies. 
 
DISCUSSION 
This systematic review and meta-analysis demonstrated that baseline physical frailty is a 
statistically significant predictor of Alzheimer’s disease, vascular dementia, and all dementia 
among community-dwelling older people. Among four previous studies examining the 
associations of frailty with incident Alzheimer’s disease, we confirmed moderate 
heterogeneity and no evidence of publication bias. A random-effects meta-regression analysis 
showed that women with frailty had a higher risk of Alzheimer’s disease than men with 
frailty. 
 
We observed that pooled risk estimates of incident Alzheimer’s disease (pooled HR=1.28) 
and all dementia (pooled HR=1.33) were relatively smaller than that of vascular dementia 
(pooled HR=2.70). There has recently been a growing interest in complex pathophysiological 
processes of Alzheimer’s disease, which were shown to precede early clinical symptoms by 
decades.1,30 Follow-up periods of the included studies for Alzheimer’s disease and all 
dementia ranged from three16 to seven years15 and may be too short to capture overall 
predictive properties of frailty, leading to smaller risk estimates for Alzheimer’s disease. This 
may be supported by the findings of a previous study showing that frailty based on FI better 
predicted incident Alzheimer’s disease (area under the curve (AUC)=0.66 vs. 0.64) and all 
dementia (AUC=0.66 vs. 0.64) over 10 years rather than over 5 years.19  
 
Two studies19,20 from the Canadian Study of Health and Aging used a deficit accumulation 
model of frailty, the FI, to examine risks of incident Alzheimer’s disease19 and all 
dementia19,20. In the first study,19 the FI with 19 non-traditional dementia risk factors 
predicted all dementia (adjusted OR=1.02 per approximately a 0.03 increase in FI, 95% 
CI=1.01–1.04, p=0.04) independently of traditional risk factors, but did not predict 
Alzheimer’s disease (adjusted OR=1.01, 95% CI=1.00–1.03, p=0.06) over 10 years. In the 
second study,20 the FI with up to 42 deficits (both traditional and non-traditional dementia 
risk factors) predicted incident all dementia (age-adjusted OR=1.18, 95% CI=1.12–1.25 in 
men and age-adjusted OR=1.08, 95% CI=1.04–1.11 in women, both per each deficit added). 
These findings that a higher degree of frailty status described by the FI was a significant risk 
factor for dementia were in line with our meta-analysis results. Although it is unknown why 
the FI, especially the one based on non-traditional dementia risk factors, predicted newly 
developing dementia, the authors hypothesized that an aberrant repair mechanism was 
involved.20 
 
The mechanisms and pathophysiology underlying the increased risks of dementia in frail 
older people are not clear at present, but both frailty and dementia are complex and 
heterogeneous entities and are known to share multiple risk factors for their development, 
including diabetes mellitus, heart attack, hypertension, congestive heart failure, 
cerebrovascular disease, and chronic inflammation.16,18,31,32 It is plausible that frailty and 
dementia result from the same underlying pathophysiology such as pathological brain 
changes.16,33,34 Recent research from the Rush Memory and Aging Project and Religious 
Orders Study using longitudinal frailty data over time and brain pathology findings from 
autopsies showed that Alzheimer’s disease pathology was associated with frailty status near 
death33 and that four brain pathology types: macroinfarcts, Alzheimer’s disease and Lewy 
body pathology, and nigral neuronal loss, were significantly associated with a more rapid 
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progression of frailty, independent of age, gender, and education.34 The brain pathology was 
only examined at autopsy and, as a matter of course, its baseline data or onset and transition 
while participants were alive were lacking.34 Despite the availability of transitional data on 
frailty status over time,34 it could not be inferred based on these findings whether brain 
pathology contributed to frailty progression or progressive frailty accumulated brain 
pathology, or whether they co-occurred. 
 
Another possibility is that cognitive impairment might be a part of frailty, rather than being 
two distinct entities that are common and often co-occurring in old age. Many experts have 
suggested that cognitive function should be included as one of the frailty criteria, and the 
International Academy on Nutrition and Aging and the International Association of 
Gerontology and Geriatrics advocated a new term, “cognitive frailty”, as a heterogeneous 
clinical state characterized by manifesting both physical frailty and cognitive impairment 
without Alzheimer’s disease or other dementia.35 It could be speculated from this theory that 
subclinical cognitive pathophysiology may have started as a part of frailty years before overt 
dementia developed and frailty seemingly preceded and predicted the development of 
dementia. Furthermore, a previous study showed that a FI incorporating multidimensional 
factors, including physical and cognitive components, better predicted adverse outcomes than 
CHS criteria, which include only physical components.36 Another study demonstrated that 
adding cognitive impairment to CHS criteria improved ability to predict adverse outcomes, 
including mobility disability, activities of daily living (ADL)/ instrumental activities of daily 
living (IADL) disability, hospitalization, and death; however, this was not the case for 
dementia.29 Cognitive impairment was shown to be associated with an approximately five-
fold increased risk of developing dementia irrespective of frailty status.29 Furthermore, there 
were no significant associations between frailty status and incident dementia, nor was there a 
dose-response relationship in risk measures according to frailty status in the entire cohort or 
in subgroups with and without cognitive impairment.29 These findings suggested that frailty 
and cognitive impairment were separate processes.29 If frailty and cognitive 
impairment/dementia were distinct entities, their interactions may have been bidirectional, 
exacerbating each other in a vicious cycle, as several cross-sectional and longitudinal studies 
have showed that people with dementia or cognitive impairment were more likely to be frail 
or become frail.37-41  
 
Our meta-regression analysis suggested higher risk of incident Alzheimer’s disease according 
to physical frailty in women than in men. The reason why women had higher risk is not clear 
at present, but we think one possible explanation for this gender disparity is age-related 
reduction in sex steroid hormones in both men and women. The deposit of amyloid-β peptide 
in the brain is considered as a pathological hallmark of Alzheimer’s disease.42 Mitochondria 
produces more reactive oxygen species when amyloid-β peptide is present43 and it has been 
proposed that increased oxidative stress plays an important role in amyloid-β peptide-induced 
neuronal cell apoptosis in Alzheimer’s disease.44 Frailty has also been shown to be associated 
with oxidative stress,45,46 which may contribute to increased risks of incidence Alzheimer’s 
disease in frail older people. Both estrogen and testosterone are neuroprotective in 
Alzheimer’s disease,47 especially against oxidative stress.48-50 While men experience a 
gradual decrease in testosterone, women have a rapid loss of estrogen after menopause. As a 
result, older women may be more susceptible to developing Alzheimer’s disease than older 
men. 
 
This study has multiple strengths. First, our comprehensive and reproducible search strategy 
was robust using extensive search words and multiple electronic databases. The screening of 
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the title, abstract, and full-text and data extraction were conducted by two researchers 
independently. Between-study variance was further explored using a meta-regression 
analysis, which showed that the female proportion of the cohorts was a significant modulator. 
Second, the overall quality of the four studies included in the meta-analysis and meta-
regression analysis was high; all studies used CHS criteria to define physical frailty and 
standardized criteria to diagnose dementia, and presented HRs adjusted for important 
confounders including age, gender, and education. These factors may have contributed to low 
to moderate heterogeneity across the studies. Lastly, it is of note that the current review and 
meta-analysis study demonstrated the pooled evidence that physical frailty predicted the 
incidence of Alzheimer’s disease, vascular dementia, and all dementia, given that the findings 
from previous studies were conflicting and a rigorous meta-analysis had not been conducted. 
 
Our results should be interpreted with caution because of potential limitations. First, the 
follow-up periods of the studies included in the meta-analyses may be too short to elucidate 
true associations between frailty and subsequent risks of incident dementia for the 
aforementioned reason, which could underestimate the risks. Second, since dementia has not 
frequently been studied in relation to frailty, there were only a limited number of studies 
available for review. Therefore publication bias and meta-regression analysis were performed 
only for the four studies on Alzheimer’s disease. Third, all studies included in this review 
were from North America or Europe. Therefore, our findings may not be generalizable to 
older people in other country and further investigation is needed to explore the association of 
frailty with dementia among other population. Lastly, all CHS criteria used by the four 
studies included in the meta-analysis were not original versions but were modified slightly 
from study to study. These modifications may have potentially affected the findings.51 
 
An increasing amount of evidence on frailty has been accumulated in the literature and the 
theoretical concept of frailty syndrome has gained universal consensus.7,52 However, its 
implementation and translation into clinical settings have not been well achieved. It is not 
always practical to measure the frailty status of older people during a busy clinic visit 
because of the lack of time, space, or equipment. For example, in CHS criteria, one needs to 
measure gait speed and grip strength as well as to identify the lowest 20% of the cohort that 
the patient belongs to while one needs to go over a list of as many as 30 or more health 
deficits in order to construct the FI. Beside CHS and FI, which are the two most popular 
frailty definitions, some researchers attempted to use methods that were more feasible, such 
as a tool consisting of five simple questions,53 or even walking speed as a single-item 
screening tool.54 These tools can be assessed for validity, which may lead to accelerating the 
translation of frailty research into clinical use for the risk screening of dementia as well as 
other adverse health outcomes. 
 
Conclusion 
This systematic review and meta-analysis demonstrated pooled evidence suggesting that 
frailty was a significant predictor of dementia, including Alzheimer’s disease, vascular 
dementia, and all dementia, among community-dwelling older people. As frailty is a dynamic 
condition and its status can change over time, interventions against frailty may provide the 
additional benefit of potentially preventing or delaying dementia. 
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Table 1. Summary of prospective studies examining baseline frailty status and subsequent 
risks of incident dementia among community-dwelling older people. 
Author/Year Study (Location) 
Sample 
size 
Female 
(%) 
Mean age 
(range) 
Frailty 
criteria 
diagnostic criteria 
Follow-
up period 
Effect 
measure 
NOS 
Alzheimer’s disease 
Gray et al. 2013 
Adult Changes in 
Thought (USA) 
2619 60.1% 
76.8 
(>=65) 
mCHS NINCDS-ADRDA 6.5 years aHR 8/9 
Solfrizzi et al. 2013 
Italian Longitudinal 
Study of Aging 
(Italy) 
2581 45.2% 
73.1 
(65-84) 
mCHS NINCDS-ADRDA 3.5 years aHR 8/9 
Avila-Funes et al. 
2012 
Three-City Study 
(France) 
5480 61.7% 
74.0 
(65-95) 
mCHS DSM-III-R 7 years aHR 8/9 
Buchman et al. 2007 
Rush Memory and 
Aging Project 
(USA) 
823 74.6% 80.4 mCHS NINCDS-ADRDA 3 years aHR 8/9 
Song et al. 2011 
Canadian Study of 
Health and Aging 
(Canada) 
2599 - 
- 
(>=65) 
FI NINCDS-ADRDA 10 years aOR 7/9 
Vascular dementia 
Solfrizzi et al. 2013 
Italian Longitudinal 
Study of Aging 
(Italy) 
2581 45.2% 
73.1 
(65-84) 
mCHS ICD-10 3.5 years aHR 8/9 
Avila-Funes et al. 
2012 
Three-City Study 
(France) 
5480 61.7% 
74.0 
(65-95) 
mCHS NINCDS-AIREN 7 years aHR 8/9 
All dementia 
Gray et al. 2013 
Adult Changes in 
Thought (USA) 
2619 60.1% 
76.8 
(>=65) 
mCHS DSM-IV 6.5 years aHR 8/9 
Solfrizzi et al. 2013 
Italian Longitudinal 
Study of Aging 
(Italy) 
2581 45.2% 
73.1 
(65-84) 
mCHS DSM-III-R 3.5 years aHR 8/9 
Avila-Funes et al. 
2012 
Three-City Study 
(France) 
5480 61.7% 
74.0 
(65-95) 
mCHS DSM-III-R 7 years aHR 8/9 
Avila-Funes et al. 
2009 
Three-City Study 
(France) 
4827 61.2% 
74.1 
(65-95) 
mCHS DSM-IV 4 years aHR 8/9 
Song et al. 2014 
Canadian Study of 
Health and Aging 
(Canada) 
2902 0% 
- 
(>=65) 
FI DSM-III-R 10 years aOR 6/9 
Song et al. 2014 
Canadian Study of 
Health and Aging 
(Canada) 
4337 100% 
- 
(>=65) 
FI DSM-III-R 10 years aOR 6/9 
Song et al. 2011 
Canadian Study of 
Health and Aging 
(Canada) 
2790 - 
- 
(>=65) 
FI DSM-III-R 10 years aOR 7/9 
Other dementia category (not included in meta-analysis) 
Gray et al. 2013 
(Non-AD dementia) 
Adult Changes in 
Thought (USA) 
2619 60.1% 
76.8 
(>=65) 
mCHS DSM-IV 6.5 years aHR 8/9 
Solfrizzi et al. 2013 
( Non-AD non-VaD 
dementia) 
Italian Longitudinal 
Study of Aging 
(Italy) 
2581 45.2% 
73.1 
(65-84) 
mCHS ICD-10 3.5 years aHR 8/9 
AD: Alzhemer’s disease 
aOR: Adjusted odds ratio 
aHR: Adjusted hazard ratio 
DSM: Diagnostic and Statistical Manual of Mental Disorders 
FI: Frailty Index 
ICD: International Statistical Classification of Diseases and Related Health Problems 
mCHS: Modified Cardiovascular Health Study frailty index (Fried’s phenotype) 
NINCDS-AIREN: National Institute of Neurological and Communicative Disorders and 
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Stroke-Association Internationale pour la Recherche en l’Enseignement en Neurosciences 
NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and 
Stroke and Alzheimer’s Disease and Related Disorders Association 
VaD: Vascular dementia 
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Figure 1. Systematic review flow chart of study selection process 
 
 
  2,564 studies identified through database searching 
   Embase (n=1,127) 
   MEDLINE (n=1,026) 
   CINAHL Plus (n=218) 
   PsycINFO (n=147) 
   Cochrane Library (n=46) 
 
1 additional study identified through other 
sources 
1,733 studies screened for titles and abstracts 
11 studies for full-text review 
Total of 2,565 studies identified 
832 duplicated studies excluded 
1,722 studies excluded by screening title 
(n=1,710) and abstract (n=12) 
 
7 studies for methodological quality assessment 
4 studies excluded by full-text review 
   Outcome not dementia (n=2) 
   Editorial or comment (n=2)    
4 studies for meta-analysis 
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Figure 2. Forest plots of incident Alzheimer’s disease, vascular dementia, and all dementia 
risk according to frailty and prefrailty. 
A. Alzheimer’s disease 
 
B Vascular dementia 
 
C All dementia 
 
 
  
16 
 
 
Figure 3. Bubble plot with fitted meta-regression line (black) along with 95% confidence 
interval lines (gray) for the association between female proportion and risk of incident 
Alzheimer’s disease by frailty. 
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